- Home
- AZI vs RNTX Comparison
AZI vs RNTX Comparison
Compare AZI & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZI
- RNTX
- Stock Information
- Founded
- AZI 2010
- RNTX 2001
- Country
- AZI China
- RNTX United States
- Employees
- AZI N/A
- RNTX N/A
- Industry
- AZI
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- AZI
- RNTX Health Care
- Exchange
- AZI Nasdaq
- RNTX Nasdaq
- Market Cap
- AZI 25.2M
- RNTX 28.0M
- IPO Year
- AZI 2024
- RNTX N/A
- Fundamental
- Price
- AZI $0.21
- RNTX $1.16
- Analyst Decision
- AZI
- RNTX Buy
- Analyst Count
- AZI 0
- RNTX 2
- Target Price
- AZI N/A
- RNTX $10.00
- AVG Volume (30 Days)
- AZI 3.5M
- RNTX 253.0K
- Earning Date
- AZI 01-01-0001
- RNTX 11-13-2025
- Dividend Yield
- AZI N/A
- RNTX N/A
- EPS Growth
- AZI N/A
- RNTX N/A
- EPS
- AZI N/A
- RNTX N/A
- Revenue
- AZI $156,466,000.00
- RNTX N/A
- Revenue This Year
- AZI N/A
- RNTX N/A
- Revenue Next Year
- AZI N/A
- RNTX N/A
- P/E Ratio
- AZI N/A
- RNTX N/A
- Revenue Growth
- AZI 32.90
- RNTX N/A
- 52 Week Low
- AZI $0.18
- RNTX $1.04
- 52 Week High
- AZI $3.20
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- AZI 45.82
- RNTX 46.84
- Support Level
- AZI $0.20
- RNTX $1.12
- Resistance Level
- AZI $0.21
- RNTX $1.25
- Average True Range (ATR)
- AZI 0.02
- RNTX 0.12
- MACD
- AZI 0.00
- RNTX 0.00
- Stochastic Oscillator
- AZI 38.40
- RNTX 34.67
About AZI Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
Autozi Internet Technology (Global) Ltd provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels in China. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, It has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the new car sales segment, and auto parts & auto accessories sales.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.